#Italy #Castelvecchio Pascoli #Kedrion #Immunodeficiencies #IPIC 2025

Kedrion's Impact at IPIC 2025: Pioneering Innovations in Immunodeficiencies

Kedrion Biopharma, a leading biopharmaceutical company renowned for plasma-derived therapies, recently announced its participation in the International Congress on Primary Immunodeficiencies (IPIC) 2025, taking place in Prague, Czech Republic, from November 5 to 7, 2025. This significant event aims to shine a light on crucial issues surrounding immunodeficiencies, particularly secondary immunodeficiencies (SI) associated with hematological malignancies, which has become a growing field of interest within immunology.

The highlight of Kedrion's involvement is the organization of a dedicated Satellite Symposium titled, "Secondary Immunodeficiencies in Hematological Neoplasias: A Growing Area of Concern." The symposium is set to commence with an introduction from Dr. Fabian Peissker from Kedrion’s Medical Affairs Department. Esteemed experts including Professor Hermann Wolf from Sigmund Freud University in Vienna, and Dr. Federica Pulvirenti from Umberto I Polyclinic in Rome, will be contributing their expertise, tackling the challenges and advancements in the diagnosis and treatment of secondary immunodeficiencies in patients with hematological conditions.

Understanding Secondary Immunodeficiencies

Secondary immunodeficiencies present significant clinical challenges, especially in patients suffering from B-cell hematologic neoplasms. Their complex pathogenesis increases the risk of potentially lethal infections, despite significant improvements in oncology therapies that have bolstered survival rates. However, complications such as hypogammaglobulinemia and infections can compromise treatment efficacy and overall patient quality of life. Early diagnosis and appropriate treatments, including immunoglobulin replacement therapies, are critical to enhance patient care and minimize infection-related complications.

Kedrion's participation in IPIC 2025 underscores its unwavering commitment to advancing scientific knowledge and fostering collaboration within the medical community, particularly regarding secondary immunodeficiencies. By sponsoring a symposium dedicated to this area, Kedrion illustrates its growing dedication to this critical and evolving field.

More Than Just a Symposium

In addition to the symposium, Kedrion will have a prominent presence with an informative booth, three scientific poster sessions, and delegates from all over the globe. This reinforces the company’s commitment to innovation in addressing immunodeficiencies. The poster sessions, developed in collaboration with leading experts and patient advocacy groups, will showcase the latest scientific advancements and the impact of ongoing research to further the understanding of immunodeficiencies.

Participants will have access to medical experts and scientists from Kedrion throughout the congress, facilitating a valuable exchange of information and discussions. Roberto Crea, head of Kedrion's immunology therapeutics, points out that numerous questions remain about the intricate interactions between primary and secondary immunodeficiencies. Thus, further research is essential to effectively understand how these conditions interact and influence each other, ensuring that better care is provided to patients. Kedrion is actively working to broaden the awareness around these issues and the need for shared guidelines to recognize patient needs, encouraging collaboration among all health system stakeholders. Crea emphasizes, “Only by working together can we enhance the outcomes and quality of life for individuals living with these diseases.”

Collaboration Is Key

Martine Pergent, president of IPOPI (International Patient Organization for Primary Immunodeficiencies), highlights the importance of collaboration, stressing the value of leveraging expertise across the spectrum of immunodeficiencies to meet the needs of patients with severe immunodeficiency syndromes. She explains, "Primary immunodeficiencies can no longer be defined solely by infections; they represent a broader spectrum of conditions with overlapping complex clinical features."

Martine further notes the logical approach of addressing secondary immunodeficiencies, as the knowledge gained in managing chronic diseases and preventing infections within the framework of primary immunodeficiencies is tremendously beneficial in catering to the needs of patients with secondary immunodeficiencies. A closer collaboration is necessary to integrate new medical experts, particularly hematologists treating secondary immunodeficiencies, and build connections with those managing primary immunodeficiencies, ultimately enhancing long-term management and quality of life for these patients while gathering real-world data that accurately reflects their situations and needs.

A Platform for Excellence

IPIC stands as a premier multidisciplinary international congress dedicated to primary immunodeficiencies and congenital immunodeficiencies, with a patient-centered focus. The 2025 edition anticipates participation from over 900 attendees representing more than 70 countries, providing a unique platform for scientific exchange and collaboration.

The Satellite Symposium sponsored by Kedrion is open to all participants, allowing attendees to explore the latest advancements relating to secondary immunodeficiencies. Attendees can also engage with scientific insights and expert perspectives at Kedrion's booth (Number 17), where more information about advancements in managing immunodeficiencies will be accessible.

For more information on Kedrion and its innovative initiatives, visit www.kedrion.com.